NADOLOL- nadolol tablet

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

NADOLOL (UNII: FEN504330V) (NADOLOL - UNII:FEN504330V)

제공처:

Bryant Ranch Prepack

관리 경로:

ORAL

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

Nadolol tablets USP are indicated for the long-term management of patients with angina pectoris. Nadolol tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pres

제품 요약:

Product: 63629-7483 NDC: 63629-7483-1 30 TABLET in a BOTTLE NDC: 63629-7483-2 28 TABLET in a BOTTLE

승인 상태:

Abbreviated New Drug Application

제품 특성 요약

NADOLOL- NADOLOL TABLET
BRYANT RANCH PREPACK
----------
NADOLOL TABLETS USP
DESCRIPTION
Nadolol is a synthetic nonselective beta-adrenergic receptor blocking
agent designated chemically as
1-(_tert_-butylamino)-3-[(5, 6, 7, 8-tetrahydro-_cis_-6,
7-dihydroxy-1-naphthyl)oxy]-2-propanol. Structural
formula:
C H NO M.W. 309.4 0
Nadolol is a white crystalline powder. It is freely soluble in
ethanol, soluble in hydrochloric acid,
slightly soluble in water and in chloroform, and very slightly soluble
in sodium hydroxide.
Nadolol tablets USP are available for oral administration as 20 mg, 40
mg and 80 mg tablets. Inactive
ingredients: lactose monohydrate, microcrystalline cellulose,
pregelatinized starch, croscarmellose
sodium, hydroxypropyl cellulose, silicon dioxide, magnesium stearate,
and purified water.
CLINICAL PHARMACOLOGY
Nadolol is a nonselective beta-adrenergic receptor blocking agent.
Clinical pharmacology studies have
demonstrated beta-blocking activity by showing (1) reduction in heart
rate and cardiac output at rest and
on exercise, (2) reduction of systolic and diastolic blood pressure at
rest and on exercise, (3) inhibition
of isoproterenol-induced tachycardia, and (4) reduction of reflex
orthostatic tachycardia.
Nadolol specifically competes with beta-adrenergic receptor agonists
for available beta receptor sites;
it inhibits both the beta receptors located chiefly in cardiac muscle
and the beta receptors located
chiefly in the bronchial and vascular musculature, inhibiting the
chronotropic, inotropic, and vasodilator
responses to beta-adrenergic stimulation proportionately. Nadolol
tablets have no intrinsic
sympathomimetic activity and, unlike some other beta-adrenergic
blocking agents, nadolol has little
direct myocardial depressant activity and does not have an
anesthetic-like membrane-stabilizing action.
Animal and human studies show that nadolol slows the sinus rate and
depresses AV conduction. In dogs,
only minimal amounts of nadolol were detected in the brain relative to
amounts in blood and other